Hexilak Gel 20GM (Polydimethylsiloxane)

Description

Hexilak Gel 20GM (Polydimethylsiloxane) — Complete Clinical and Patient Information Guide

Product Overview

Hexilak Gel 20GM (Polydimethylsiloxane) contains Polydimethylsiloxane (silicone gel) 100% as its active pharmaceutical ingredient, belonging to the medical-grade silicone gel for scar management. It is clinically indicated for hypertrophic scars, keloids, post-surgical scars, post-burn scars, stretch marks, and other abnormal scar formations. This comprehensive guide has been developed in accordance with YMYL (Your Money Your Life) content standards, drawing on regulatory prescribing information, peer-reviewed pharmacological literature, and established clinical guidelines to provide accurate, evidence-based information for patients and healthcare professionals.

Hexilak Gel is a medical-grade silicone scar management preparation supported by systematic reviews and international consensus guidelines from plastic surgery, dermatology, and wound care organisations as the first-line conservative treatment for hypertrophic scars. Its non-pharmacological, physical mechanism means it can be safely combined with virtually any other scar management approach.

Understanding Hexilak Gel and Its Active Ingredient

Polydimethylsiloxane (silicone gel) 100% is the pharmacologically active compound in Hexilak Gel. The drug class to which it belongs — medical-grade silicone gel for scar management — has a well-established clinical evidence base developed across decades of research, regulatory review, and real-world clinical use. Understanding the mechanism of action, appropriate therapeutic use, necessary monitoring, and safety considerations of this medication is essential for achieving optimal clinical outcomes while protecting patient safety.

This product should only be used under appropriate medical supervision. For medications classified as YMYL (conditions where improper use carries significant health risk), professional medical guidance before initiating, modifying, or stopping therapy is not optional — it is a fundamental patient safety requirement. Patients are encouraged to maintain open, honest communication with their prescribing physician and pharmacist about all aspects of their treatment.

Mechanism of Action

Polydimethylsiloxane (PDMS) is a silicone polymer used in topical scar management gels (Hexilak Gel) as the primary active vehicle. Silicone gel’s mechanism of action in scar management involves several physical and biological processes: it creates an occlusive, semi-permeable barrier over the scar surface that increases hydration of the stratum corneum (reducing TEWL — trans-epidermal water loss). This hydration reduces fibroblast activation in the underlying dermis — dehydration of the stratum corneum is a potent stimulus for fibroblast proliferation and collagen overproduction characteristic of hypertrophic and keloid scar formation. Adequately hydrated skin surface signals fibroblasts via mechanotransduction pathways to reduce collagen synthesis and increase matrix metalloproteinase (MMP)-mediated collagen remodelling, progressively softening and flattening the scar. Additionally, silicone gel generates a static electrical field across the treated skin that may influence fibroblast orientation and differentiation. The result over weeks to months of consistent wear is softening, flattening, fading, and improved pliability of hypertrophic scars — the primary indication for medical-grade silicone gel products.

Understanding how this medication works at the molecular and cellular level helps explain the clinical requirements for optimal use: why specific timing, administration conditions, monitoring tests, contraindications, and drug interactions exist. Healthcare providers apply this mechanistic understanding to individualise therapy, anticipate drug interactions, counsel patients on what to expect, and monitor for treatment response and toxicity.

Clinical Indications

Hexilak Gel 20GM (Polydimethylsiloxane) is clinically indicated for:

• Primary indication: hypertrophic scars, keloids, post-surgical scars, post-burn scars, stretch marks, and other abnormal scar formations
• Confirmed diagnosis required: A qualified healthcare professional must confirm the diagnosis and determine appropriateness of this specific medication for the individual patient. Self-diagnosis and self-treatment with prescription medications carries significant and potentially serious health risks.
• Treatment goals and monitoring: The prescribing physician establishes clear therapeutic objectives and a monitoring plan appropriate to the specific indication and the patient’s individual risk profile.

Dosage and Administration

Apply a thin layer of Hexilak Gel to the clean, dry, fully closed scar surface twice daily. Gently massage in with circular motions until absorbed (1–2 minutes). Allow to dry completely before covering with clothing. For optimal results, apply consistently throughout the day — some dermatologists recommend combined use with a silicone sheet (tape) at night for occlusive benefit. Begin treatment as soon as wounds have fully closed (typically 2 weeks after surgical closure) for best outcomes. Continue for a minimum of 2–3 months for hypertrophic scars; 3–6 months for keloids.

Adherence to the prescribed dosing regimen is critical for therapeutic success and patient safety. Patients uncertain about their dosing schedule should contact their prescribing physician or pharmacist before making any changes. Never alter doses or stop therapy without medical advice, particularly for medications (such as systemic retinoids, alcohol dependence therapies, and corticosteroids) where abrupt changes can have significant consequences.

Who Should Use Hexilak Gel

Hexilak Gel is indicated for adult patients (and where specified, adolescent patients) who have been diagnosed by a qualified healthcare professional with the conditions listed in the indications section, and for whom this medication has been determined appropriate following assessment of individual benefits and risks. Patients should have no absolute contraindications and should be able to comply with any required monitoring or safety programme requirements.

Contraindications — Who Should Not Use Hexilak Gel

Hypersensitivity to silicone or any excipient (rare). Do not apply to open wounds or wounds that have not fully epithelialised. Avoid contact with eyes.

Before starting Hexilak Gel, patients must provide their prescribing physician with a complete medical history, including all current medications (prescription and over-the-counter), known allergies, and relevant personal and family medical history. Conditions that appear unrelated to the treatment indication may significantly affect prescribing decisions for drugs with complex safety profiles.

Drug Interactions

No clinically significant systemic drug interactions — silicone gel is not absorbed systemically. May create an occlusive barrier that reduces absorption of other topical products applied simultaneously — apply Hexilak Gel after other topical medications have been absorbed.

Drug interactions can be clinically significant and potentially dangerous. A complete medication review by a qualified pharmacist or physician is essential before starting Hexilak Gel. Many interactions can be effectively managed through dose adjustment, temporal separation of doses, or alternative drug selection — but only when proactively identified. Patients should never add new medications (including herbal supplements and over-the-counter products) without checking for interactions with Hexilak Gel.

Adverse Effects and Side Effects

Generally very well tolerated. Possible: mild pruritus (itching) over the treated scar during initial weeks of treatment (this may represent active scar remodelling). Skin rash or contact dermatitis (rare). Maceration under occlusive silicone gel with excessive application (avoid thick layers). Silicone gel is not associated with systemic toxicity.

Side effects vary in frequency, severity, and clinical significance. Patients should be educated before starting treatment about which side effects to expect and manage (expected retinisation with retinoids, mucocutaneous dryness with isotretinoin) versus which require prompt medical attention (signs of disulfiram-ethanol reaction, symptoms of pseudotumour cerebri, signs of hepatotoxicity). A proactive approach to side-effect education significantly improves treatment adherence and patient safety.

Special Population Considerations

Timing of initiation: early treatment of newly formed scars (within 2 weeks of wound closure) produces significantly better outcomes than treating established scars. The physiology of scar maturation allows more effective intervention during the active remodelling phase (3–18 months post-injury) than once scars have fully matured. Patient commitment: scar treatment requires months of consistent twice-daily application — adherence is the primary predictor of outcome. Unrealistic expectations should be addressed proactively: even optimal treatment does not eliminate scars but significantly improves their appearance, texture, and pliability.

Storage and Handling

Store Hexilak Gel at room temperature (15–25°C) in a dry location away from direct sunlight, heat sources, and moisture. Keep in the original manufacturer’s packaging until required. Secure out of reach of children and pets. Do not use beyond the printed expiry date. Dispose of unused or expired medication through authorised pharmaceutical take-back services — do not flush down drains or discard in household waste, as pharmaceutical waste poses environmental hazards.

Frequently Asked Questions

Q: How should I store this medication?
A: Store at room temperature (15–25°C), away from direct sunlight, heat, and moisture. Keep in original packaging out of reach of children and pets. Do not use beyond the printed expiry date.

Q: What should I do if I miss a dose?
A: Take the missed dose as soon as you remember, unless it is nearly time for the next scheduled dose. Never double-dose. Consult your prescriber if uncertain about how to manage a missed dose in your specific regimen.

Q: How does silicone gel help scars?
A: Silicone gel’s primary mechanism is scar hydration — it creates an occlusive semi-permeable layer over the scar surface that dramatically reduces water loss from the skin surface. This hydration reduces fibroblast activity in the underlying dermis (dehydration is a potent stimulus for excess collagen production), progressively softening and flattening the scar. Consistent twice-daily application for months is required for meaningful improvement.

Q: Is silicone gel better than other scar treatments?
A: Silicone gel (sheets and gels) is the most evidence-supported conservative treatment for hypertrophic scars and has the endorsement of international wound healing and plastic surgery societies. For keloids — which are more aggressive scar formations extending beyond the wound boundaries — silicone gel is effective as part of a multimodal approach that may include intralesional steroid injections, pressure therapy, or laser treatment for optimal outcomes.

Clinical Evidence and Quality Standards

The active ingredient in Hexilak Gel has been evaluated in randomised controlled trials, meta-analyses, and extensive post-marketing surveillance studies supporting its use in the approved indications. Major international clinical guidelines — including those from the British Association of Dermatologists, American Academy of Dermatology, European Dermatology Forum, National Institute for Health and Care Excellence (NICE), and relevant specialty societies — incorporate this drug class in their evidence-based treatment algorithms, reflecting a high level of clinical confidence in its efficacy and safety profile when used appropriately.

Hexilak Gel is manufactured in compliance with Good Manufacturing Practice (GMP) standards required by national and international pharmaceutical regulatory authorities. GMP certification ensures consistent product quality, identity, strength, purity, and safety across all manufactured batches. Patients should only obtain prescription medications from licensed pharmacies with a valid prescription to ensure they receive authentic, properly stored, regulatory-compliant products.

Evidence Base and Clinical Guidelines

The active ingredient(s) in this product have been evaluated in randomised controlled trials, systematic reviews, and extensive real-world clinical experience. Major international clinical guidelines — including those from the British Association of Dermatologists, American Academy of Dermatology, European Dermatology Forum, National Institute for Health and Care Excellence (NICE), WHO Model Formulary, and relevant specialty societies — incorporate this drug class in their evidence-based treatment algorithms. The level of clinical confidence reflected in guideline recommendations is commensurate with the quality and consistency of supporting clinical evidence accumulated over years of research and practice.

Evidence-based prescribing requires matching the right treatment to the right patient at the right dose for the right duration — a principle that applies with particular importance to prescription dermatological and addiction medicine agents. Healthcare providers are encouraged to consult current approved prescribing information in their jurisdiction, as recommendations evolve with accumulating evidence.

Patient Education and Adherence

Treatment outcomes with this medication are significantly influenced by patient understanding and consistent adherence. Key patient education points include:

• Realistic expectations: Most acne treatments require 8–12 weeks of consistent use before full benefit is apparent. Premature discontinuation based on perceived lack of early response is the most common cause of inadequate acne treatment outcomes. For addiction medicine treatments, sustained engagement over 12–24 months produces far better outcomes than short-term pharmacotherapy.
• Consistency: Irregular use of topical dermatological products significantly reduces their efficacy. Topical retinoids applied only on lesion-by-lesion basis rather than across the entire acne-prone area underperform compared to whole-region daily application. For oral addiction medicines, daily dosing maintains therapeutic plasma levels essential for consistent pharmacological benefit.
• Side-effect management: Many side effects of dermatological medications — retinoid-induced dryness, initial acne flare, GI effects from antibiotics — are predictable, manageable, and temporary. Proactive counselling and supportive care prevent unnecessary treatment discontinuation due to manageable adverse effects that would otherwise resolve with continued treatment.
• Complementary measures: Non-pharmacological measures — sun protection, gentle skincare, dietary modifications, stress management, psychological support — significantly enhance the outcomes of both dermatological and addiction medicine pharmacotherapy.

Responsible Medication Use

Prescription medications should be obtained exclusively from licensed pharmacies with a valid prescription from a registered healthcare provider. Purchasing prescription medications from unlicensed online sources carries substantial risk of receiving counterfeit, substandard, incorrectly labelled, or contaminated products. Counterfeit dermatological medications have been associated with serious skin reactions, while counterfeit addiction medicine products may contain incorrect or dangerous substances. Patient safety demands obtaining medications through legitimate, regulated supply chains.

All unused or expired medications should be returned to a licensed pharmacy for safe disposal. Pharmaceutical waste poses environmental risks when flushed or discarded in household waste, and proper disposal prevents accidental access by children or others for whom the medication was not intended.

Important Medical Disclaimer

This product information page is provided for general educational purposes only, developed in accordance with YMYL (Your Money Your Life) content standards. The information presented draws on regulatory prescribing information, peer-reviewed pharmacological literature, and established clinical guidelines. It is not a substitute for professional medical advice, diagnosis, or treatment from a qualified physician, dermatologist, addiction medicine specialist, or pharmacist. Drug therapy decisions must be individualised based on the complete clinical picture, comorbidities, and concurrent medications of each patient. Self-diagnosis and self-treatment of conditions managed by prescription medications can be dangerous and may lead to delayed diagnosis of serious underlying conditions, inappropriate drug use, or preventable adverse events. Always consult a qualified healthcare professional before starting, changing, or stopping this or any medication.